# A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

> **NCT03953079** · PHASE2 · COMPLETED · sponsor: **Graybug Vision** · enrollment: 56 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** Drug: GB-102
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT03953079
- **Lead sponsor:** Graybug Vision
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-26
- **Primary completion:** 2020-12-15
- **Final completion:** 2021-06-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03953079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03953079, "A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03953079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*